

CITATION REPORT

List of articles citing

A randomized, double-blind, single-dose study to evaluate the biosimilarity of QL1101 with bevacizumab in healthy male subjects

DOI: 10.1007/s00280-019-04014-x

Cancer Chemotherapy and Pharmacology, 2020, 85, 555-562.

Source: <https://exaly.com/paper-pdf/75167155/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
10	A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers. <i>Cancer Chemotherapy and Pharmacology</i> , 2020 , 86, 567-575	3.5	4
9	A randomized, double-blind, parallel-group, single-dose, pharmacokinetic bioequivalence study of INTP24 and bevacizumab in healthy adult men. <i>Cancer Chemotherapy and Pharmacology</i> , 2020 , 86, 193-202	3.5	1
8	A pharmacokinetics study of proposed bevacizumab biosimilar MYL-14020 vs EU-bevacizumab and US-bevacizumab. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 1	4.9	3
7	A Randomized, Double-Blind, Single-Dose Study Comparing the Biosimilarity of HOT-1010 With Bevacizumab (Avastin®) in Chinese Healthy Male Subjects. <i>Frontiers in Pharmacology</i> , 2021 , 12, 694375	5.6	0
6	The changing landscape of anti-lung cancer drug clinical trials in mainland China from 2005 to 2020. <i>The Lancet Regional Health - Western Pacific</i> , 2021 , 11, 100151	5	0
5	Pharmacokinetic bioequivalence, safety, and immunogenicity of GB222, a bevacizumab biosimilar candidate, and bevacizumab in Chinese healthy males: a randomized clinical trial. <i>Expert Opinion on Biological Therapy</i> , 2021 , 1-10	5.4	2
4	Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial. <i>Cancer Biology and Medicine</i> , 2021 ,	5.2	6
3	Biosimilar monoclonal antibodies in China: A patent review. <i>Bioengineered</i> , 2022 , 13, 14503-14518	5.7	
2	Efficacy and safety of adding bevacizumab biosimilar or original drug to platinum-based chemotherapy as first-line treatment in patients with advanced NSCLC: a systematic review and meta-analysis. 2022 , 14, 175883592211305		0
1	Emerging role of biosimilars: Focus on Bevacizumab and hepatocellular carcinoma. 2023 , 387-402		0